Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia

Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical science monitor 2011-07, Vol.17 (7), p.CR376-CR380
Hauptverfasser: Kaya, Ali, Uysal, Ismail Önder, Güven, Ahmet Sami, Engin, Aynur, Gültürk, Abdulaziz, İçağasıoğlu, Füsun Dilara, Cevit, Ömer
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page CR380
container_issue 7
container_start_page CR376
container_title Medical science monitor
container_volume 17
creator Kaya, Ali
Uysal, Ismail Önder
Güven, Ahmet Sami
Engin, Aynur
Gültürk, Abdulaziz
İçağasıoğlu, Füsun Dilara
Cevit, Ömer
description Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection. We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (
doi_str_mv 10.12659/MSM.881848
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3539565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>874186825</sourcerecordid><originalsourceid>FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</originalsourceid><addsrcrecordid>eNpVUU1Lw0AQXUSxtXryLrl5kNT9yH7kIkjxC1oEredlkmzalXy5myj-e1dbi8LAzDCP9x7zEDoleEqo4Onl4nkxVYqoRO2hMREJi5nkeD_MlCUxwQSP0JH3rxhTJTA_RCNKJE4FI2P0tHQG-to0fVSCrQZnoraMVmGH2ua2iUJ1prDQO5tHHfQ2nHz0Yft11Lq2W4P7bFYGqqgfKnCmtnCMDkqovDnZ9gl6ub1Zzu7j-ePdw-x6HudM4T4WgghsZCHSQhEsuWQYZ4xnvIQMRKoo8ExICsEnFIRDQhQmxAhOCc5TydgEXW14uyGrTZEHYw4q3TlbB1O6Bav_Xxq71qv2XTPOUi54IDjfErj2bTC-17X1uakqaEw7eK1k0BSKfiMvNsjctd47U-5UCNY_IegQgt6EENBnf43tsL9fZ1-0h4Mo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>874186825</pqid></control><display><type>article</type><title>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>PubMed Central</source><creator>Kaya, Ali ; Uysal, Ismail Önder ; Güven, Ahmet Sami ; Engin, Aynur ; Gültürk, Abdulaziz ; İçağasıoğlu, Füsun Dilara ; Cevit, Ömer</creator><creatorcontrib>Kaya, Ali ; Uysal, Ismail Önder ; Güven, Ahmet Sami ; Engin, Aynur ; Gültürk, Abdulaziz ; İçağasıoğlu, Füsun Dilara ; Cevit, Ömer</creatorcontrib><description>Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection. We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (&lt;1 cm). All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.</description><identifier>ISSN: 1234-1010</identifier><identifier>EISSN: 1643-3750</identifier><identifier>DOI: 10.12659/MSM.881848</identifier><identifier>PMID: 21709631</identifier><language>eng</language><publisher>United States: International Scientific Literature, Inc</publisher><subject>Adolescent ; Child ; Clinical Research ; Female ; Gentamicins - therapeutic use ; Humans ; Lymph Nodes - pathology ; Male ; Retrospective Studies ; Streptomycin - therapeutic use ; Treatment Failure ; Tularemia - drug therapy ; Tularemia - pathology ; Turkey</subject><ispartof>Medical science monitor, 2011-07, Vol.17 (7), p.CR376-CR380</ispartof><rights>Med Sci Monit, 2011 2011</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</citedby><cites>FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539565/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3539565/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21709631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaya, Ali</creatorcontrib><creatorcontrib>Uysal, Ismail Önder</creatorcontrib><creatorcontrib>Güven, Ahmet Sami</creatorcontrib><creatorcontrib>Engin, Aynur</creatorcontrib><creatorcontrib>Gültürk, Abdulaziz</creatorcontrib><creatorcontrib>İçağasıoğlu, Füsun Dilara</creatorcontrib><creatorcontrib>Cevit, Ömer</creatorcontrib><title>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</title><title>Medical science monitor</title><addtitle>Med Sci Monit</addtitle><description>Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection. We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (&lt;1 cm). All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.</description><subject>Adolescent</subject><subject>Child</subject><subject>Clinical Research</subject><subject>Female</subject><subject>Gentamicins - therapeutic use</subject><subject>Humans</subject><subject>Lymph Nodes - pathology</subject><subject>Male</subject><subject>Retrospective Studies</subject><subject>Streptomycin - therapeutic use</subject><subject>Treatment Failure</subject><subject>Tularemia - drug therapy</subject><subject>Tularemia - pathology</subject><subject>Turkey</subject><issn>1234-1010</issn><issn>1643-3750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVUU1Lw0AQXUSxtXryLrl5kNT9yH7kIkjxC1oEredlkmzalXy5myj-e1dbi8LAzDCP9x7zEDoleEqo4Onl4nkxVYqoRO2hMREJi5nkeD_MlCUxwQSP0JH3rxhTJTA_RCNKJE4FI2P0tHQG-to0fVSCrQZnoraMVmGH2ua2iUJ1prDQO5tHHfQ2nHz0Yft11Lq2W4P7bFYGqqgfKnCmtnCMDkqovDnZ9gl6ub1Zzu7j-ePdw-x6HudM4T4WgghsZCHSQhEsuWQYZ4xnvIQMRKoo8ExICsEnFIRDQhQmxAhOCc5TydgEXW14uyGrTZEHYw4q3TlbB1O6Bav_Xxq71qv2XTPOUi54IDjfErj2bTC-17X1uakqaEw7eK1k0BSKfiMvNsjctd47U-5UCNY_IegQgt6EENBnf43tsL9fZ1-0h4Mo</recordid><startdate>20110701</startdate><enddate>20110701</enddate><creator>Kaya, Ali</creator><creator>Uysal, Ismail Önder</creator><creator>Güven, Ahmet Sami</creator><creator>Engin, Aynur</creator><creator>Gültürk, Abdulaziz</creator><creator>İçağasıoğlu, Füsun Dilara</creator><creator>Cevit, Ömer</creator><general>International Scientific Literature, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20110701</creationdate><title>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</title><author>Kaya, Ali ; Uysal, Ismail Önder ; Güven, Ahmet Sami ; Engin, Aynur ; Gültürk, Abdulaziz ; İçağasıoğlu, Füsun Dilara ; Cevit, Ömer</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c380t-66160e7d69d810757300b35b5faba6982a5b672a963ad15a418011e65210c9733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Adolescent</topic><topic>Child</topic><topic>Clinical Research</topic><topic>Female</topic><topic>Gentamicins - therapeutic use</topic><topic>Humans</topic><topic>Lymph Nodes - pathology</topic><topic>Male</topic><topic>Retrospective Studies</topic><topic>Streptomycin - therapeutic use</topic><topic>Treatment Failure</topic><topic>Tularemia - drug therapy</topic><topic>Tularemia - pathology</topic><topic>Turkey</topic><toplevel>online_resources</toplevel><creatorcontrib>Kaya, Ali</creatorcontrib><creatorcontrib>Uysal, Ismail Önder</creatorcontrib><creatorcontrib>Güven, Ahmet Sami</creatorcontrib><creatorcontrib>Engin, Aynur</creatorcontrib><creatorcontrib>Gültürk, Abdulaziz</creatorcontrib><creatorcontrib>İçağasıoğlu, Füsun Dilara</creatorcontrib><creatorcontrib>Cevit, Ömer</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical science monitor</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaya, Ali</au><au>Uysal, Ismail Önder</au><au>Güven, Ahmet Sami</au><au>Engin, Aynur</au><au>Gültürk, Abdulaziz</au><au>İçağasıoğlu, Füsun Dilara</au><au>Cevit, Ömer</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia</atitle><jtitle>Medical science monitor</jtitle><addtitle>Med Sci Monit</addtitle><date>2011-07-01</date><risdate>2011</risdate><volume>17</volume><issue>7</issue><spage>CR376</spage><epage>CR380</epage><pages>CR376-CR380</pages><issn>1234-1010</issn><eissn>1643-3750</eissn><abstract>Tularemia is a zoonotic infection, and the causative agent is Francisella tularensis. A first-line therapy for treating tularemia is aminoglycosides (streptomycin or, more commonly, gentamicin), and treatment duration is typically 7 to 10 days, with longer courses for more severe cases. We evaluated 11 patients retrospectively. Failure of the therapy was defined by persistent or recurrent fever, increased size or appearance of new lymphadenopathies and persistence of the constitutional syndrome with elevation of the levels of the proteins associated with the acute phase of infection. We observed fluctuating size of lymph nodes of 4 patients who were on the 7th day of empirical therapy. The therapy was switched to streptomycin alone and continued for 14 days. The other 7 patients, who had no complications, were on cefazolin and gentamycin therapy until the serologic diagnosis. Then we evaluated them again and observed that none of their lymph nodes regressed. We also switched their therapy to 14 days of streptomycin. After the 14 days on streptomycin therapy, we observed all the lymph nodes had recovered or regressed. During a follow-up 3 weeks later, we observed that all their lymph nodes had regressed to the clinically non-significant dimensions (&lt;1 cm). All patients were first treated with gentamicin, but were than given streptomycin after failure of gentamicin. This treatment was successful in all patients. The results of our study suggest that streptomycin is an effective choice of first-line treatment for pediatric oropharyngeal tularemia patients.</abstract><cop>United States</cop><pub>International Scientific Literature, Inc</pub><pmid>21709631</pmid><doi>10.12659/MSM.881848</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1234-1010
ispartof Medical science monitor, 2011-07, Vol.17 (7), p.CR376-CR380
issn 1234-1010
1643-3750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3539565
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; PubMed Central
subjects Adolescent
Child
Clinical Research
Female
Gentamicins - therapeutic use
Humans
Lymph Nodes - pathology
Male
Retrospective Studies
Streptomycin - therapeutic use
Treatment Failure
Tularemia - drug therapy
Tularemia - pathology
Turkey
title Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T18%3A21%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20failure%20of%20gentamicin%20in%20pediatric%20patients%20with%20oropharyngeal%20tularemia&rft.jtitle=Medical%20science%20monitor&rft.au=Kaya,%20Ali&rft.date=2011-07-01&rft.volume=17&rft.issue=7&rft.spage=CR376&rft.epage=CR380&rft.pages=CR376-CR380&rft.issn=1234-1010&rft.eissn=1643-3750&rft_id=info:doi/10.12659/MSM.881848&rft_dat=%3Cproquest_pubme%3E874186825%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=874186825&rft_id=info:pmid/21709631&rfr_iscdi=true